SLC6A7/PROT Polyclonal Antibody, HRP Conjugated
Référence bs-12124R-HRP
Conditionnement : 100ul
Marque : Bioss
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
SLC6A7/PROT Polyclonal Antibody, HRP Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-12124R-HRP |
| Product Name | SLC6A7/PROT Polyclonal Antibody, HRP Conjugated |
| Applications | ELISA, IHC-P, IHC-F |
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Chicken |
| Specifications | |
| Conjugation | HRP |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human SLC6A7/PROT |
| Immunogen Range | 151-260/636 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Subcellular location | Cell membrane |
| Synonyms | SC6A7_HUMAN; Slc6a7; Sodium-dependent proline transporter; Solute carrier family 6 member 7. |
| Background | The GAT1 gene family includes sodium- and chloride-dependent plasma membrane transporters for neurotransmitters, metabolites and osmolites, which couple substrate flux to transmembrane electrochemical gradients. PROT (Sodium-dependent proline transporter), also known as Solute carrier family 6 member 7, is a 636 amino acid multi-pass membrane protein that is a GAT1 family member specifically expressed in regions of the brain. PROT terminates the action of proline by its high affinity sodium/chloride-dependent reuptake into pre-synaptic terminals. Enriched in glutamatergic synaptic terminals, it is likely that PROT plays an important role in excitatory events of neurotransmission. PROT-mediated proline uptake is inhibited by compounds such as benztropine, LP-403812 and Des-Tyr-Leu-enkephalin (GGFL). These inhibitors of proline uptake may lead to the development of therapeutic agents for certain neurologic disorders. |
| Application Dilution | |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |